Ameliorative effect of montelukast against STZ induced diabetic nephropathy: targeting HMGB1, TLR4, NF-kappa B, NLRP3 inflammasome, and autophagy pathways

Diabetic nephropathy (DN) is reported as one of the most serious microvascular diabetic complications and the trigger of end-stage renal disease (ESRD), underscoring the concern of any therapeutic intervention directed at ameliorating the development and progression of DN. The current study explored the renoprotective impact of montelukast (Mon) against streptozotocin (STZ)-induced DN in rats compared to a standard anti-hyperglycemic insulin (Ins) treatment. Diabetes was induced by a single dose of STZ (55 mg/kg). Diabetic rats were treated with Mon (10 and 20 mg/kg, oral gavage) for eight weeks. Mon administration for 8 weeks after induction of diabetes conferred significant dose-dependent renoprotection, independent of blood glucose levels (unlike Ins), as evidenced by the improvement in serum creatinine, and blood urea nitrogen (BUN), and ameliorated STZ- induced renal necrotic, inflammatory alterations, and renal fibrosis. Additionally, Mon treatment in diabetic rats significantly restored redox hemostasis as evidenced by malondialdehyde (MDA) and total antioxidant capacity (TAC) levels; significantly reduced the renal expression of high mobility group box (HMGB) 1, tolllike receptor (TLR) 4, nuclear factor kappa B (NF-kappa B) (in the nucleus), NOD-like receptor family pyrin domain containing (NLRP) 3, and interleukin (IL)- 1 beta. Moreover, Mon administration ameliorated the dysregulation in autophagy as evidenced by p62 and microtubule-associated protein 1A/1B-light chain 3 (LC3)-II levels. In conclusion, the renoprotective effect of Mon is potentially associated with its modulatory effect on inflammatory cytokines, antioxidant properties, and autophagy. [GRAPHICS] [GRAPHICS]

Automated summary

This study explored the renoprotective effect of montelukast (Mon) in streptozotocin (STZ)-induced diabetic nephropathy (DN) in rats compared to a standard insulin treatment. Mon administration for 8 weeks significantly improved renal function, reduced inflammation and fibrosis, restored redox hemostasis, and ameliorated dysregulation in autophagy. The renoprotective effect of Mon is potentially associated with its modulation of inflammatory cytokines, antioxidant properties, and autophagy.